• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events

ISNTD d3 2021

24-25 February 2021

Virtual conference

ISNTD d³ 2021 addresses the current gaps and collaboration opportunities across tropical diseases and diseases of poverty to accelerate drug discovery & development, vaccine R&D and uptake, and diagnostics and surveillance opportunities. 

This year, against the backdrop of the recently launched WHO NTD Roadmap and the shock of the COVID-19 pandemic, ISNTD d³ focuses on the shifts, gaps, and future needs of drug discovery, treatments, and diagnostics in context of global health as well as broader challenges.

Panel discussions

Rethinking financial incentives for drugs and diagnostics for Neglected Tropical Diseases

Date: Wednesday, 24 February 2021
Time: 9.00-10.00 UTC

Chair: Andrew Jack, Financial Times

Speakers:

  • Dr Hayato Urabe, Senior Director, Investment Strategy, Portfolio Development & Innovations, GHIT Fund
  • Olawale Ajose, Head of Access, Neglected Tropical Diseases, DNDi
  • Dr Beatrice Greco, Head of R&D and Access, Global Health Institute, Merck
  • Margo Warren, Government Engagement & Policy Manager, Access to Medicine Foundation

Putting access at the centre of future drug development

Date: Wednesday, 24 February 2021
Time: 10.15-11.45 UTC

Speakers:

  • Margo Warren, Government Engagement & Policy Manager, Access to Medicine Foundation
  • Dr Isaac Chikwanha, Senior Director: Investment Strategy, Access & Delivery, GHIT Fund
  • Olawale Ajose, Head of Access, Neglected Tropical Diseases, DNDi
  • The Leprosy Mission England & Wales patient voices

 

Drug repurposing for COVID19 & neglected tropical diseases

Date: Wednesday, 24 February 2021
Time: 13.15-14.45 UTC

Speakers:

  • Dr Nathalie Strub-Wourgaft, Director of Neglected Tropical Diseases, DNDi
  • Heather Stone, Health Science Policy Analyst, US Food & Drug Administration

Focus: leishmaniasis

Date: Wednesday, 24 February 2021
Time: 15.00-16.30 UTC

Current and future treatments for visceral leishmaniasis 
Prof Maria Paola Costi, Drug Discovery and Biotechnology Lab, University of Modena and Reggio Emilia, UNIMORE
Dr Fabiana Alves, Head of Visceral Leishmaniasis Clinical Programme, DNDi
The development of new treatments for cutaneous leishmaniasis, opportunities, and gaps
Dr Byron Arana, Head of Cutaneous Leishmaniasis, DNDi
Topical treatments for cutaneous leishmaniasis 
Prof Dolores Carrer, Biophysics and Nanotechnology Lab, INIMEC-CONICET-UNC, Argentina
Biophysical characterization and integrated MD simulation studies of trypanothione reductase in leishmania major
Anurag Kumar, Computational & Systems Biology Lab, National Centre For Cell Science, Pune, Maharashtra, India

More information

  • Event website

Registration & access Cutaneous leishmaniasis Pandemic Preparedness Visceral leishmaniasis

Other events

Loading...
15-20 June 2025

Kigali, Rwanda

Twelfth EDCTP Forum

15-18 June 2025

Manila, Philippines

8th Asia Dengue Summit

22 May 2025

Online event

MSF Scientific Days

21 May 2025, 9-10:30 AM

Geneva, Switzerland

Scaling impact: Climate & health solutions that drive change

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License